Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter

IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

See all formats and pricing
More options …
Volume 38, Issue 9


Cancer Therapy and Polymorphisms of Cytochromes P450

Stewart L. MacLeod / Susan Nowell / Joyce Massengill / Abdul Jazieh / Gail McClure / Jason Plaxco / Fred F. Kadlubar / Nicholas P. Lang
Published Online: 2005-06-01 | DOI: https://doi.org/10.1515/CCLM.2000.128


Cytochrome P450 (CYP) enzymes are important in the metabolism of some endogenous compounds, environmental and dietary xenobiotics and many drugs. Many of these enzymes have genetic polymorphisms that produce significant changes in metabolic activity, however the function of other polymorphisms is unknown. Genetic polymorphisms have important influences on variability in human pharmacokinetics, including intra-individual differences in drug toxicity, drug interactions and response to chemotherapy. Other factors that influence drug metabolism include differences in enzyme expression due to differences in age, gender, smoking status, exposure to dietary or environmental xenobiotics or co-administration of other drugs. In addition, some xenobiotics and drugs can directly inhibit or induce the activity of CYPs. All of these factors can produce differences in metabolic capacities among individuals which can produce toxicity in some patients and sub-effective dosing in others. Maximum clinical benefit will require a more complete understanding of the influence of these polymorphisms on allele function and their interaction with inducers and inhibitors of enzyme expression or activity. This effort will permit the pharmacogenetic screening of patients before the administration of drugs and result in the identification of individuals who are prone to adverse reactions or poor response, resulting in more effective individualized therapy.

About the article

Published Online: 2005-06-01

Published in Print: 2000-09-18

Citation Information: Clinical Chemistry and Laboratory Medicine, Volume 38, Issue 9, Pages 883–887, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2000.128.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Lichuan Liu, Huadong Sun, Wiqas Y. Valji, and K. Sandy Pang
American Journal of Physiology-Gastrointestinal and Liver Physiology, 2007, Volume 293, Number 5, Page G1078
Beate Klimm, Thorsten Reineke, Heinz Haverkamp, Karolin Behringer, Hans T. Eich, Andreas Josting, Beate Pfistner, Volker Diehl, and Andreas Engert
Journal of Clinical Oncology, 2005, Volume 23, Number 31, Page 8003
Isa E. L. M. Kuppens, P. Breedveld, J. H. Beijnen, and J. H. M. Schellens
Cancer Investigation, 2005, Volume 23, Number 5, Page 443
Anne M. Larson
Clinics in Liver Disease, 2007, Volume 11, Number 3, Page 525
David I. Quinn, John Nemunaitis, Jyotsna Fuloria, Carolyn D. Britten, Nashat Gabrail, Lorrin Yee, Milin Acharya, Kai Chan, Nadine Cohen, and Assen Dudov
Clinical Pharmacokinetics, 2009, Volume 48, Number 3, Page 199
K K Jain
Expert Opinion on Pharmacotherapy, 2005, Volume 6, Number 9, Page 1463
Esther F. A. Brandon, Rolf W. Sparidans, Ronald D. van Ooijen, Irma Meijerman, Luis Lopez Lazaro, Ignacio Manzanares, Jos H. Beijnen, and Jan H. M. Schellens
Investigational New Drugs, 2007, Volume 25, Number 1, Page 9
Bertrand Rochat
Clinical Pharmacokinetics, 2005, Volume 44, Number 4, Page 349
L. E. Schmidt and K. Dalhoff
Alimentary Pharmacology and Therapeutics, 2003, Volume 18, Number 10, Page 979

Comments (0)

Please log in or register to comment.
Log in